Xavier Garcia del Muro

Xavier Garcia del Muro is a senior sarcoma oncologist who played a pivotal role in the development and regulatory approval of trabectedin (Yondelis) for soft tissue sarcomas, particularly leiomyosarcoma and liposarcoma. As scientific director of the Spanish Group for Research on Sarcomas (GEIS), he coordinated multicenter clinical trials and translational research programs. His work has contributed to understanding trabectedin's mechanism of action, predictive biomarkers, and optimal clinical integration into STS treatment algorithms. He has also been involved in trials of olaratumab and other investigational agents in STS.